<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">69719</article-id><article-id pub-id-type="doi">10.7554/eLife.69719</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-235797"><name><surname>Anisul</surname><given-names>Mohd</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2960-6017</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-237985"><name><surname>Shilts</surname><given-names>Jarrod</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-237988"><name><surname>Schwartzentruber</surname><given-names>Jeremy</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-237986"><name><surname>Hayhurst</surname><given-names>James</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-237987"><name><surname>Buniello</surname><given-names>Annalisa</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-237989"><name><surname>Shaikho</surname><given-names>Elmutaz</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-87267"><name><surname>Zheng</surname><given-names>Jie</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6623-6839</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-185466"><name><surname>Holmes</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-121652"><name><surname>Ochoa</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-237990"><name><surname>Carmona</surname><given-names>Miguel</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" id="author-237991"><name><surname>Maranville</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-87279"><name><surname>Gaunt</surname><given-names>Tom R</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0924-3247</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf11"/></contrib><contrib contrib-type="author" id="author-237992"><name><surname>Emilsson</surname><given-names>Valur</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-93667"><name><surname>Gudnason</surname><given-names>Vilmundur</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5696-0084</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-237993"><name><surname>McDonagh</surname><given-names>Ellen M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf12"/></contrib><contrib contrib-type="author" id="author-17265"><name><surname>Wright</surname><given-names>Gavin J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0537-0863</contrib-id><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-237994"><name><surname>Ghoussaini</surname><given-names>Maya</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf13"/></contrib><contrib contrib-type="author" corresp="yes" id="author-6225"><name><surname>Dunham</surname><given-names>Ian</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2525-5598</contrib-id><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="fn" rid="conf14"/></contrib><aff id="aff1"><institution>Wellcome Sanger Institute</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution>EBI-EMBL</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution>Bristol-Myers Squibb</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Medical Research Council (MRC) Integrative Epidemiology Unit, Department of  Population Health Sciences</institution>, <institution>University of Bristol</institution>, <addr-line><named-content content-type="city">Bristol</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff5"><institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff6"><institution content-type="dept">MRC Integrative Epidemiology Unit</institution>, <institution>University of Bristol</institution>, <addr-line><named-content content-type="city">Bristol</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff7"><institution>Icelandic Heart Association</institution>, <addr-line><named-content content-type="city">Kopavogur</named-content></addr-line>, <country>Iceland</country></aff><aff id="aff8"><institution content-type="dept">Cell Surface Signalling Laboratory</institution>, <institution>Wellcome Trust Sanger Institute</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff9"><institution content-type="dept">Open Targets</institution>, <institution>EMBL-European Bioinformatics Institute</institution>, <addr-line><named-content content-type="city">Hinxton</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-62461"><name><surname>Schoggins</surname><given-names>John W</given-names></name><role>Reviewing editor</role><aff><institution>University of Texas Southwestern Medical Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>mk31@sanger.ac.uk</email> (MA);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>mg29@sanger.ac.uk</email> (MG);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>dunham@ebi.ac.uk</email> (ID);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>17</day><month>08</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e69719</elocation-id><history><date date-type="received"><day>23</day><month>04</month><year>2021</year></date><date date-type="accepted"><day>07</day><month>08</month><year>2021</year></date></history><permissions><copyright-statement>Â© 2021, Anisul et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Anisul et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-69719-v1.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>The virus SARS-CoV-2 can exploit biological vulnerabilities (e.g. host proteins) in susceptible hosts that predispose to the development of severe COVID-19.</p></sec><sec id="abs2"><title>Methods:</title><p>To identify host proteins that may contribute to the risk of severe COVID-19, we undertook proteome-wide genetic colocalisation tests, and polygenic (pan) and cis-Mendelian randomisation analyses leveraging publicly available protein and COVID-19 datasets.</p></sec><sec id="abs3"><title>Results:</title><p>Our analytic approach identified several known targets (e.g. ABO, OAS1), but also nominated new proteins such as soluble Fas (colocalisation probability &gt; 0.9, p = 1 x 10<sup>-4</sup>), implicating Fas-mediated apoptosis as a potential target for COVID-19 risk. The polygenic (pan) and cis-Mendelian randomisation analyses showed consistent associations of genetically predicted ABO protein with several COVID-19 phenotypes. The <italic>ABO</italic> signal is highly pleiotropic and a look-up of proteins associated with the <italic>ABO</italic> signal revealed that the strongest association was with soluble CD209. We demonstrated experimentally that CD209 directly interacts with the spike protein of SARS-CoV-2, suggesting a mechanism that could explain the ABO association with COVID-19.</p></sec><sec id="abs4"><title>Conclusions:</title><p>Our work provides a prioritised list of host targets potentially exploited by SARS-CoV-2 and is a precursor for further research on CD209 and FAS as therapeutically tractable targets for COVID-19.</p></sec><sec id="abs5"><title>Funding:</title><p>MAK, JSc, JH, AB, DO, MC, EMM, MG, ID were funded by Open Targets. J.Z. and T.R.G were funded by the UK Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/4). JSh and GJW were funded by the Wellcome Trust Grant 206194. This research was funded in part by the Wellcome Trust [Grant 206194]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.</p></sec></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>Grant 206194</award-id><principal-award-recipient><name><surname>Anisul</surname><given-names>Mohd</given-names></name><name><surname>Shilts</surname><given-names>Jarrod</given-names></name><name><surname>Schwartzentruber</surname><given-names>Jeremy</given-names></name><name><surname>Wright</surname><given-names>Gavin J</given-names></name><name><surname>Ghoussaini</surname><given-names>Maya</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Mohd Anisul, Open Targets is a pre-competitive partnership currently involving the Wellcome Sanger Institute, EMBL-EBI, BMS, GSK, and Sanofi. Research is funded by financial and in-kind contributions from each of the partners..</p></fn><fn fn-type="conflict" id="conf3"><p>Jeremy Schwartzentruber, Open Targets is a pre-competitive partnership currently involving the Wellcome Sanger Institute, EMBL-EBI, BMS, GSK, and Sanofi. Research is funded by financial and in-kind contributions from each of the partners..</p></fn><fn fn-type="conflict" id="conf4"><p>James Hayhurst, Open Targets is a pre-competitive partnership currently involving the Wellcome Sanger Institute, EMBL-EBI, BMS, GSK, and Sanofi. Research is funded by financial and in-kind contributions from each of the partners..</p></fn><fn fn-type="conflict" id="conf5"><p>Annalisa Buniello, Open Targets is a pre-competitive partnership currently involving the Wellcome Sanger Institute, EMBL-EBI, BMS, GSK, and Sanofi. Research is funded by financial and in-kind contributions from each of the partners..</p></fn><fn fn-type="conflict" id="conf6"><p>Elmutaz Shaikho, Open Targets is a pre-competitive partnership currently involving the Wellcome Sanger Institute, EMBL-EBI, BMS, GSK, and Sanofi. Research is funded by financial and in-kind contributions from each of the partners.. ES is also a full-time employee of Bristol-Myers Squibb..</p></fn><fn fn-type="conflict" id="conf7"><p>Michael Holmes, Dr Holmes has consulted for Boehringer Ingelheim, and in adherence to the University of Oxford's Clinical Trial Service Unit &amp; Epidemiological Studies Unit (CSTU) staff policy, did not accept personal honoraria or other payments from pharmaceutical companies..</p></fn><fn fn-type="conflict" id="conf8"><p>David Ochoa, Open Targets is a pre-competitive partnership currently involving the Wellcome Sanger Institute, EMBL-EBI, BMS, GSK, and Sanofi. Research is funded by financial and in-kind contributions from each of the partners..</p></fn><fn fn-type="conflict" id="conf9"><p>Miguel Carmona, Open Targets is a pre-competitive partnership currently involving the Wellcome Sanger Institute, EMBL-EBI, BMS, GSK, and Sanofi. Research is funded by financial and in-kind contributions from each of the partners..</p></fn><fn fn-type="conflict" id="conf10"><p>Joseph Maranville, JM is a full-time employee of Bristol-Myers Squibb and retains stock or stock options in Bristol-Myers Squibb. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf11"><p>Tom R Gaunt, TG received grants from Biogen and GlaxoSmithKline. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf12"><p>Ellen M McDonagh, Open Targets is a pre-competitive partnership currently involving the Wellcome Sanger Institute, EMBL-EBI, BMS, GSK, and Sanofi. Research is funded by financial and in-kind contributions from each of the partners..</p></fn><fn fn-type="conflict" id="conf13"><p>Maya Ghoussaini, Open Targets is a pre-competitive partnership currently involving the Wellcome Sanger Institute, EMBL-EBI, BMS, GSK, and Sanofi. Research is funded by financial and in-kind contributions from each of the partners..</p></fn><fn fn-type="conflict" id="conf14"><p>Ian Dunham, Open Targets is a pre-competitive partnership currently involving the Wellcome Sanger Institute, EMBL-EBI, BMS, GSK, and Sanofi. Research is funded by financial and in-kind contributions from each of the partners. ID also received travel costs within the last 36 months from Takeda for speaking at their Reverse Translation Symposium. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: All institutions contributing cohorts to the COVID-19 Host Genetics Initiative and INTERVAL (Sun et al) study for proteomics received ethics approval from their respective research ethics review boards. All participants in the INTERVAL study provided informed consent before joining the INTERVAL study with approval from the National Research Ethics (11/EE/0538). Ethics statements of studies that contributed participant data to the COVID-19 Host Genetics Initiative are provided in Supplementary Table 1 of their recently published paper (https://www.nature.com/articles/s41586-021-03767-x).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Summary data used for genetic analyses are publicly available (Sun et al can be downloaded from GWAS catalog https://www.ebi.ac.uk/gwas/downloads/summary-statistics and COVID-19 HGI summary statistics can be downloaded from their website https://www.covid19hg.org/results/). Data generated from our study are provided in the supplementary tables (pan-MR and cis-MR association results filtered at p &lt; 0.05 and no filters applied to colocalisation results).</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Sun et al</collab></person-group><year iso-8601-date="2018">2018</year><source>Genomic atlas of the human plasma proteome</source><ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/gwas/downloads/summary-statistics">https://www.ebi.ac.uk/gwas/downloads/summary-statistics</ext-link><comment>GWAS Catalog, GCST005806</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>The COVID-19 Host Genetics Initiative</collab></person-group><year iso-8601-date="2021">2021</year><source>Mapping the human genetic architecture of COVID-19 by worldwide meta-analysis</source><ext-link ext-link-type="uri" xlink:href="https://www.covid19hg.org/results/">https://www.covid19hg.org/results/</ext-link><comment>COVID GWAS meta-analysis results, release 4</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-69719-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>